Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER
2023-510366-28-00Phase 2Authorised
- Sponsor
- Ferrer
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing FNP-223 with Placebo (2 arms). Primary endpoints: Change from baseline to Week 52 in the total score of the full 28-item PSPRS, Change from baseline to Week 52 in the total score of the mPSPRS-10 and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
ASN120290
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2023-510366-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510366-28-00.